Literature DB >> 14678857

Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement.

F J Drummond1, P Annis, K O'Sullivan, F Wynne, M Daly, F Shanahan, K A Quane, M G Molloy.   

Abstract

Celiac disease (CD) is a relatively common gastrointestinal disorder that can be asymptomatic. An increased prevalence of subclinical CD has been reported in many populations. Even among asymptomatic patients a reduction in bone mineral density (BMD) has been observed. The aim of this study was to evaluate the prevalence of silent CD in a cohort of consecutive individuals referred for bone densitometry measurement. Serum samples were taken from 454 women attending for bone densitometry (mean age: 56 +/- 11 years). Of the individuals evaluated, 89 had normal BMD and 365 had low BMD (T score < -1.0). Subjects were screened for the presence of serum IgA anti-endomysial antibodies (EMA) and IgA tissue transglutaminase (tTG) antibodies by indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA), respectively. BMD was measured by dual X-ray absorptiometry (DEXA) at the lumbar spine and femoral neck. Eight EMA tTG-positive individuals were identified in this population (1.8% or 1:57). Serologically positive women had a lower mean Z score at both the lumbar spine and femoral neck than EMA tTG-negative women. But this did not approach significance. There was no significant difference in the incidence of CD between the normal- and low-BMD groups in this dataset (P = 0.365). In conclusion, our study indicates that the prevalence of CD in our dataset is high. However, the frequency of asymptomatic CD among low-BMD individuals is similar to that among normal-BMD individuals in our population. These observations do not support the hypothesis that serological testing for CD may be a good accompaniment to DEXA scanning.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678857     DOI: 10.1016/j.bone.2003.07.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

1.  CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.

Authors:  Frances J Drummond; John J Mackrill; Kathleen O'sullivan; Mary Daly; Fergus Shanahan; Michael G Molloy
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  GREB1 genetic variants are associated with bone mineral density in Caucasians.

Authors:  Kevin G Hegarty; Frances J Drummond; Mary Daly; Fergus Shanahan; Michael G Molloy
Journal:  J Bone Miner Metab       Date:  2017-03-14       Impact factor: 2.626

Review 3.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

Review 4.  Bone in celiac disease.

Authors:  M-L Bianchi; M T Bardella
Journal:  Osteoporos Int       Date:  2008-04-17       Impact factor: 4.507

5.  Prevalence of IgA-antiendomysial antibody in a patient cohort with idiopathic low bone mineral density.

Authors:  T Karakan; O Ozyemisci-Taskiran; Z Gunendi; F Atalay; C Tuncer
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

Review 6.  Celiac disease and risk of fracture in adults--a review.

Authors:  A M Hjelle; E Apalset; P Mielnik; J Bollerslev; K E A Lundin; G S Tell
Journal:  Osteoporos Int       Date:  2014-04-02       Impact factor: 4.507

Review 7.  Approach to diagnosing celiac disease in patients with low bone mineral density or fragility fractures: multidisciplinary task force report.

Authors:  Lorena P Rios; Aliya Khan; Muhammad Sultan; Karen McAssey; Mona A Fouda; David Armstrong
Journal:  Can Fam Physician       Date:  2013-10       Impact factor: 3.275

Review 8.  Bone mass and mineral metabolism alterations in adult celiac disease: pathophysiology and clinical approach.

Authors:  Michele Di Stefano; Caterina Mengoli; Manuela Bergonzi; Gino Roberto Corazza
Journal:  Nutrients       Date:  2013-11-22       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.